NCT02272998View on ClinicalTrials.gov

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 24, 2015

Primary Completion Date

November 17, 2022

Study Completion Date

November 17, 2022

Conditions

Malignant Neoplasm

Interventions

DRUG

ponatinib hydrochloride

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (2)

43210

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus

48109

University of Michigan, Ann Arbor

All Listed Sponsors

lead

Sameek Roychowdhury

OTHER

NCT02272998 - Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT. | Biotech Hunter | Biotech Hunter